Antibe Therapeutics Inc.
ATBPF
$0.2156
$0.025613.47%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 17.06% | 13.31% | -64.19% | 17.52% | 31.74% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 650.25% | -119.02% | -40.25% | -20.77% | 5.64% |
| Change in Net Operating Assets | 94.64% | -271.39% | 247.38% | -206.09% | -131.46% |
| Cash from Operations | 41.06% | -40.53% | -36.39% | 5.80% | 26.79% |
| Capital Expenditure | -- | -- | -- | 118.52% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -143.08% | -- |
| Other Investing Activities | 462.42% | -73.05% | 2,244.15% | -1,848.31% | 90.94% |
| Cash from Investing | 510.83% | -73.05% | 1,314.44% | -203.57% | 400.77% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 100.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 16,100.00% | -- |
| Cash from Financing | -- | -- | -- | 16,900.00% | 97.66% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 252.57% | -328.51% | 154.37% | -23.21% | 40.21% |
